Biotech News
GSK makes strong start to 2025 with growth in sales, profits and earnings
Q1 2025 performance highlights
Related news
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
ARGXArgenx2026-07-23 05:00 EST
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
BMEABiomea Fusion2026-08-05 20:05 EST
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
INVAInnoviva2026-08-05 20:05 EST
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
GERNGeron2026-08-05 11:00 EST
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
MMSIMerit Medical2026-07-30 20:05 EST
Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
RLAYRelay Therapeutics2026-07-30 20:05 EST
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
ELVNEnliven Therapeutics2026-08-05 20:05 EST
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
SRPTSarepta Therapeutics2026-08-05 20:05 EST
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Stock data
- Close
- 52.17 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States